Disease: Bipolar Depression

Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use

mycolabadmin

This paper explores potential risks of psychedelic use in people who have experienced trauma, proposing that psychedelics might reactivate unprocessed traumatic memories and cause psychological instability. The authors suggest that while psychedelics show promise for treating depression and PTSD, people with trauma histories need careful screening and support before, during, and after use. They recommend body-focused therapies and strong social support to help safely integrate traumatic material that might surface during psychedelic experiences.

Read More »

The therapeutic potential of microdosing psychedelics in depression

mycolabadmin

This review examines whether taking very small doses of psychedelic drugs like LSD and psilocybin might help treat depression. While users report benefits and some studies show subtle positive effects on mood and thinking, scientists have not yet confirmed whether microdosing actually works as a depression treatment. More research with depressed patients is needed to understand if this approach is truly helpful and safe for regular use.

Read More »

Hype or hope? Ketamine for the treatment of depression: results from the application of deep learning to Twitter posts from 2010 to 2023

mycolabadmin

Researchers analyzed over 18,000 Twitter posts from 2010 to 2023 to understand what the public thinks about using ketamine to treat depression. They found that public opinion became much more positive after the FDA approved ketamine as a depression treatment in 2019. Most discussions consisted of personal stories from people who found ketamine helpful, especially those whose depression didn’t respond to other medications. While some people expressed caution and concerns, overall the public seems hopeful about ketamine’s potential.

Read More »

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models

mycolabadmin

This paper addresses confusion about how ketamine and psychedelics are being used to treat mental health conditions like depression and PTSD. The authors propose new clear definitions to distinguish whether these drugs are used alone for their chemical effects, combined with established talk therapies, or used to create experiences that are then processed in therapy. Using these clearer definitions will help patients, doctors, and regulators better understand what treatments involve and make more informed decisions.

Read More »
Scroll to Top